Open Access

Tissue engineered vascularized periosteal flap enriched with MSC/EPCs for the treatment of large bone defects in rats

  • Authors:
    • Christoph Nau
    • Dirk Henrich
    • Caroline Seebach
    • Katrin Schröder
    • John H. Barker
    • Ingo Marzi
    • Johannes Frank
  • View Affiliations

  • Published online on: February 21, 2017     https://doi.org/10.3892/ijmm.2017.2901
  • Pages: 907-917
  • Copyright: © Nau et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Vascularized periosteal flaps are used for complex cases if the reconstruction of large bone defects is necessary in modern trauma and orthopedic surgery. In this study, we combined this surgical procedure with β‑TCP scaffold and mesenchymal stem cells (MSCs) + endothelial progenitor cells (EPCs) as a tissue engineering approach to obtain optimum conditions for bone healing in rats. A critical size femoral defect was created in 80 rats allocated into 4 groups. Defects were treated according to the following protocol: i) vascularized periosteal flap alone; ⅱ) vascularized periosteal flap + β‑TCP scaffold; ⅲ) vascularized periosteal flap + β‑TCP scaffold + ligated vascular pedicle; and ⅳ) vascularized periosteal flap + β‑TCP scaffold + MSCs/EPCs. After 8 weeks, femur bones were extracted and analyzed for new bone formation, vascularization, proliferation and inflammatory processes and strength. Bone mineral density (BMD) and biomechanical stability at week 8 were highest in group 4 (flap + β‑TCP scaffold + MSCs/EPCs) compared to all the other groups. Stability was significantly higher in group 4 (flap + β‑TCP scaffold + MSCs/EPCs) in comparison to group 3 (ligated flap + β‑TCP scaffold). BMD was found to be significantly lower in group 3 (ligated flap + β‑TCP scaffold) compared to group 1 (flap) and group 4 (flap + β‑TCP scaffold + MSCs/EPCs). The highest density of blood vessels was observed in group 4 (flap + β‑TCP + MSCs/EPCs) and the values were significantly increased in comparison to group 3 (ligated flap), but not to group 1 (flap) and group 2 (flap + β‑TCP). The highest amounts of proliferating cells were observed in group 4 (flap + β‑TCP scaffold + MSC/EPCs). The percentage of proliferating cells was significantly higher in group 4 (flap + β‑TCP scaffold + MSCs/EPCs) in comparison to all the other groups after 8 weeks. Our data thus indicate that critical size defect healing could be improved if MSCs/EPCs are added to β-TCP scaffold in combination with a periosteal flap. Even after 8 weeks, the amount of proliferating cells was increased. The flap blood supply is essential for bone healing and the reduction of inflammatory processes.
View Figures
View References

Related Articles

Journal Cover

April-2017
Volume 39 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nau C, Henrich D, Seebach C, Schröder K, Barker JH, Marzi I and Frank J: Tissue engineered vascularized periosteal flap enriched with MSC/EPCs for the treatment of large bone defects in rats. Int J Mol Med 39: 907-917, 2017
APA
Nau, C., Henrich, D., Seebach, C., Schröder, K., Barker, J.H., Marzi, I., & Frank, J. (2017). Tissue engineered vascularized periosteal flap enriched with MSC/EPCs for the treatment of large bone defects in rats. International Journal of Molecular Medicine, 39, 907-917. https://doi.org/10.3892/ijmm.2017.2901
MLA
Nau, C., Henrich, D., Seebach, C., Schröder, K., Barker, J. H., Marzi, I., Frank, J."Tissue engineered vascularized periosteal flap enriched with MSC/EPCs for the treatment of large bone defects in rats". International Journal of Molecular Medicine 39.4 (2017): 907-917.
Chicago
Nau, C., Henrich, D., Seebach, C., Schröder, K., Barker, J. H., Marzi, I., Frank, J."Tissue engineered vascularized periosteal flap enriched with MSC/EPCs for the treatment of large bone defects in rats". International Journal of Molecular Medicine 39, no. 4 (2017): 907-917. https://doi.org/10.3892/ijmm.2017.2901